ARTICLE | Clinical News
BLSI starting ADHD Phase II
August 20, 2001 7:00 AM UTC
Boston Life Sciences (BLSI) will begin this year U.S. Phase II testing of its Altropane, a radioimaging agent that binds dopamine transporter sites (DATs) in the brain, in 80 patients, ages 8-17. The ...